REFERENCES
1. IARC. Fact sheets by Population-Globocan-IARC. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.
2. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-16.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
6. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
7. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
8. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-96.
9. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8.
10. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Sci 1893;105:487-510.
11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
12. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-2.
13. Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood 2013;121:4694-702.
15. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012;1:48-55.
16. Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol 2018;15:555-67.
17. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol 2013;3:785-97.
18. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
19. Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver Dis 2014;34:376-88.
20. Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol 2019;40:228-42.
21. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology 2016;150:1646-58.e17.
22. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 2015;4:e954829.
23. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016;37:208-20.
24. Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:715-25.
25. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology 2016;64:2038-46.
26. Yan W, Liu X, Ma H, Zhang H, Song X, et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut 2015;64:1593-604.
27. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
28. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014;24:743-50.
30. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 2016;48:500-9.
31. Lee HJ, Kim SK, Cho D, Lee JJ. Cellular immunotherapy as a beacon of hope for hematological malignancies. Blood Res 2015;50:126-8.
32. Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis 2012;30:483-91.
33. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
34. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 2013;139:39-48.
35. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J cancer 2010;126:2164-74.
36. Pexa-Vec/Nexavar combination fails phase III trial in liver cancer. Available from: https://www.genengnews.com/news/pexa-vec-nexavar-combination-fails-phase-iii-trial-in-liver-cancer/. [Last accessed on 9 Oct 2019].
37. Liu D, Staveley-O’Carroll KF, Li G. Immune-based therapy clinical trials in hepatocellular carcinoma. J Clin Cell Immunol 2015;6:376.
38. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, et al. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989;10:349-53.
39. Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995;18:257-62.
40. Wang Y, Chen H, Wu M, Bao J, Cong W, et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl) 1997;110:114-7.
41. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
42. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.
43. Maus M V, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625-35.
44. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
45. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33.
46. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
47. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
48. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
49. Wainberg ZA, Segal NH, Jaeger D, Lee KH, Marshall J, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2017;35:4071.
50. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
51. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm577166.htm. [Last accessed on 10 Oct 2019].
52. Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma. Available from: https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol. [Last accessed on 10 Oct 2019].
53. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:mdz394.029.
54. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
55. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625705.htm. [Last accessed on 10 Oct 2019].
56. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019;37:abstract4004.
57. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2019;37:4012.
58. Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol 2017;35:4073.
59. Zhou Y, Xu X, Ding J, Jing X, Wang F, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther 2018;14:40-5.
60. Pishvaian MJ, Lee MS, Ryoo B, Stein S, Lee K, et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Updated-safety-and-clinical-activity-results-from-a-Phase-Ib-study-of-atezolizumab-bevacizumab-in-hepatocellular-carcinoma-HCC. [Last accessed on 10 Oct 2019].
61. FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC). Available from: https://www.roche.com/media/releases/med-cor-2018-07-18.htm. [Last accessed on 10 Oct 2019].
62. Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36:abstract4076.
63. Kudo M, Motomura K, Wada Y, Sakamoto Y, Kurosaki M. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). J Clin Oncol 2019;37:abstract4072.
64. Stein S, Pishvaian MJ, Lee MS, Lee KH, Hernandez S, et al. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol 2018;36:4074.
65. El-Khoueiry AB, Melero I, Yau TC, Crocenzi TS, Kudo M, et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. J Clin Oncol 2018;36:475.
66. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 2016;17:e542-51.
